Drew Moss

Drew Moss

Auto-generated profile, based on publicly available information

Drew Moss

Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, 10065, NY

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
FKFergus Keane
Fergus Keane
LSLily V Saadat
Lily V Saadat
COCatherine A O’cOnnor
Catherine A O’cOnnor
JCJoanne F Chou
Joanne F Chou
ABAnita S Bowman
Anita S Bowman
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
Background: The utility of circulating tumor DNA (ctDNA) in addressing challenges of molecular tissue profiling and complementing next-generation sequencing is undefined in pancreas ductal adenocarcinoma. The objective of this study was to assess ctDNA detection rates by stage, disease burden, and metastasis patterns; compare overall survival between ctDNA-positive and ctDNA-negative patients cases; and determine concordance between ctDNA and matched-tissue biopsies. Methods: Patients with pancreas ductal adenocarcinoma who had undergone Next Generation Sequencing by the MSK-ACCESS (Memorial Sloan Kettering – Analysis of Circulating cfDNA to Evaluate Somatic Status) ctDNA assay between 2019 and 2022 were included. Clinical and survival data were abstracted from a prospectively maintained clinical database. Results: A total of 414 patients with pancreas ductal adenocarcinoma: 28% stage I-II, 21% stage III, 51% stage IV. ctDNA detection was highest among patients with advanced disease: 75% stage IV, 38% stage III, 34% stage I-II disease. For stage IV, ctDNA was more frequently detected in patients with at least 2 organs involved vs with less than 2 organs involved (76% vs 38%, P = .025). Higher rates of ctDNA detection were observed in patients with liver metastases vs without (82% vs 52%, P < .001). In the untreated stage IV cohort (n = 120), median overall survival was 10 months for those with detectable ctDNA (95% CI = 6.9 to 14 months) vs 19 months (95% CI = 13 months to not reached) for those with undetectable ctDNA (P = .1). Concordance between ctDNA and matched tissue next-generation sequencing was lower in untreated stage I-III disease, but high for untreated stage IV pancreas ductal adenocarcinoma, including a critical success index of 93.1% of KRAS variants. Conclusion: ctDNA is a promising tool in the detection of somatic variants in pancreas ductal adenocarcinoma. Concordance between ctDNA and tissue is high for patients with untreated metastatic disease, notably for detection of KRAS variants.

26 October 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
FKFergus Keane
Fergus Keane
COCatherine O’cOnnor
Catherine O’cOnnor
DMDrew Moss
Drew Moss
JCJoanne F Chou
Joanne F Chou
MPMaria A Perry
Maria A Perry
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
Adjuvant mFOLFIRINOX (mFFX) is standard of care for fit individuals with resected pancreatic ductal adenocarcinoma (PDAC). There are limited data on adjuvant mFFX outcomes outside clinical trials. Institutional databases queried to identify patients with resected PDAC who received ≥1 dose adjuvant mFFX. Primary endpoints: recurrence free survival (RFS), overall survival (OS). Secondary endpoints: clinical factors, genomic features associated with outcomes. RFS and OS were estimated with Kaplan-Meier. Cox proportional hazards regression model was used to associate clinico-genomic features correlated with survival outcomes. N = 147 identified between 01/2015–01/2023. Median age: 67 years; N = 57 (39%) >70 years. Unfavorable prognostic features: N = 52 (36%) N2 nodal status, N = 115 (78%) lymphovascular invasion), and N = 133 (90%) perineural invasion. Median time from surgery to start mFFX: 1.78 months (m) (IQR 1.45, 2.12). N = 124 (84%) completed 12 doses; N = 98 (67%) stopped oxaliplatin early for neuropathy (median 10 doses; range 4-12). Further dosing characteristics are summarized in Supplementary Table 3. With median follow up of 35.1 m, median RFS (mRFS) 26 m (95% CI 19, 39) and median OS (mOS) not reached. For >70 cohort, mRFS 23 m (95% CI 14, NR) and mOS 51 m (95% CI 37, NR). mFFX started 70 years.